Remix Therapeutics to Present at 5th Annual RNA-Targeted Drug Discovery Summit

08 Dec 2022
www.globenewswire.com
siRNA
Remix Therapeutics to Present at 5th Annual RNA-Targeted Drug Discovery Summit
Company to Announce Lead Program During Podium Presentation
CAMBRIDGE, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that executive management will present at the 5th Annual RNA-Targeted Drug Discovery Summit to be held December 14-15, 2022 in Boston.
Podium Presentation:
Title:Novel Approaches to Reprogram RNA Processing with Small MoleculesDate/Time:Wednesday, December 14 at 9:30 a.m. ETPresenter:Peter Smith, Ph.D., Chief Executive Officer
Panel Discussion:
Title:Exploring the Future of RNA Investment & Collaborations Space for Small MoleculesDate/Time:Wednesday, December 14 at 11:30 a.m. ETPresenter:Heather Wasserman, Ph.D., Chief Operating Officer and Chief Business Officer “We look forward to disclosing our lead program and presenting our novel approach to reprogramming RNA processing among an audience of researchers, clinicians and other industry leaders. Our innovative REMaster technology platform holds the promise to bring effective new medicines to patients in need, and forums such as these help to advance those efforts,” said Dr. Smith.
Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease. The REMaster technology platform facilitates RNA processing pattern identification, leveraging these learnings to modulate gene expression. Remix’s innovative therapeutic approach has the ability to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin. For more information visit www.remixtx.com.
Contacts:
Media Contact:
Lissette Steele
lsteele@vergescientific.com
202-930-4762 ext. 409
Investor Contact:
Will O'Connor
Stern Investor Relations
will.oconnor@sternir.com
212-362-1200


For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.